2Seventy Bio Inc Asset Resilience Ratio

Latest as of March 2025: 16.25%

2Seventy Bio Inc asset resilience ratio. 2Seventy Bio Inc (TSVT) has an Asset Resilience Ratio of 16.25% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 2Seventy Bio Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$78.02 Million
Cash + Short-term Investments

Total Assets

$480.00 Million
All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio of 2Seventy Bio Inc (2020–2024)

Asset resilience ratio of 2Seventy Bio Inc from 2020 to 2024. This chart shows how 2Seventy Bio Inc's Asset Resilience Ratio has changed over time. Read 2Seventy Bio Inc total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down 2Seventy Bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 2Seventy Bio Inc assets under control.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $78.02 Million 16.25%
Total Liquid Assets $78.02 Million 16.25%

Asset Resilience Insights

  • Good Liquidity Position: 2Seventy Bio Inc maintains a healthy 16.25% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

2Seventy Bio Inc Industry Peers by Asset Resilience Ratio

Compare 2Seventy Bio Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 15.95%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Halozyme Therapeutics Inc
NASDAQ:HALO
Biotechnology 12.71%
Immunitybio Inc
NASDAQ:IBRX
Biotechnology 38.07%
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Biotechnology 35.63%
SOLENO THERAPEUT. DL-001
F:6XC
Biotechnology 41.74%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 37.31%
Inner Mongolia Furui Med Sci
SHE:300049
Biotechnology 3.03%

2Seventy Bio Inc Asset Resilience Ratio by Year (2020–2024)

2Seventy Bio Inc asset resilience ratio by year from 2020 to 2024. The table below shows the annual Asset Resilience Ratio data for 2Seventy Bio Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 21.59% $103.51 Million $479.51 Million -3.53pp
2023-12-31 25.12% $142.03 Million $565.43 Million -4.61pp
2022-12-31 29.73% $195.24 Million $656.66 Million +12.01pp
2021-12-31 17.72% $134.64 Million $759.67 Million --
2020-12-31 0.00% $0.00 $312.62 Million --
pp = percentage points

About 2Seventy Bio Inc

NASDAQ:TSVT USA Biotechnology
Market Cap
$266.14 Million
Market Cap Rank
#14763 Global
#3562 in USA
Share Price
$5.00
Change (1 day)
+0.00%
52-Week Range
$5.00 - $5.00
All Time High
$42.56
About

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was inco… Read more